118 related articles for article (PubMed ID: 38164693)
1. Low expression of GRM4 is associated with poor prognosis and tumor immune infiltration in glioma.
Fan H; Yan D; Fang X; Xiao L; Liang M; Wu H; Zhu G; Geng D; Liu Q
Int J Neurosci; 2024 Jan; ():1-13. PubMed ID: 38164693
[TBL] [Abstract][Full Text] [Related]
2. MCM10 as a novel prognostic biomarker and its relevance to immune infiltration in gliomas.
Tian QS; Zhang Q; Huang W
Technol Health Care; 2023; 31(4):1301-1317. PubMed ID: 36872806
[TBL] [Abstract][Full Text] [Related]
3. Elevated TYROBP expression predicts poor prognosis and high tumor immune infiltration in patients with low-grade glioma.
Lu J; Peng Y; Huang R; Feng Z; Fan Y; Wang H; Zeng Z; Ji Y; Wang Y; Wang Z
BMC Cancer; 2021 Jun; 21(1):723. PubMed ID: 34162355
[TBL] [Abstract][Full Text] [Related]
4. DNA methylation-regulated YTHDF2 correlates with cell migration and immune cell infiltration in glioma.
Jiang X; Chen X; Huang X; Wang C; Wang C; Pan C; Cho WC; Nie Z; Pu J; Wang W
Aging (Albany NY); 2022 Jun; 14(19):7774-7793. PubMed ID: 35661004
[TBL] [Abstract][Full Text] [Related]
5. MCM4 is a novel prognostic biomarker and promotes cancer cell growth in glioma.
Yang S; Yuan Y; Ren W; Wang H; Zhao Z; Zhao H; Zhao Q; Chen X; Jiang X; Zhang L
Front Oncol; 2022; 12():1004324. PubMed ID: 36465369
[TBL] [Abstract][Full Text] [Related]
6. MELK is a prognostic biomarker and correlated with immune infiltration in glioma.
Yang H; Zhou H; Wang G; Tian L; Li H; Zhang Y; Xue X
Front Neurol; 2022; 13():977180. PubMed ID: 36353126
[TBL] [Abstract][Full Text] [Related]
7. PROS1 shapes the immune-suppressive tumor microenvironment and predicts poor prognosis in glioma.
Wang J; Wu N; Feng X; Liang Y; Huang M; Li W; Hou L; Yin C
Front Immunol; 2022; 13():1052692. PubMed ID: 36685506
[TBL] [Abstract][Full Text] [Related]
8. CKS2 (CDC28 protein kinase regulatory subunit 2) is a prognostic biomarker in lower grade glioma: a study based on bioinformatic analysis and immunohistochemistry.
Hu M; Li Z; Qiu J; Zhang R; Feng J; Hu G; Ren J
Bioengineered; 2021 Dec; 12(1):5996-6009. PubMed ID: 34494924
[TBL] [Abstract][Full Text] [Related]
9. Optimized risk stratification strategy for glioma patients based on the feature genes of poor immune cell infiltration patterns.
Wan HT; Su ZJ; Guo ZS; Wen P; Hong XY
J Cancer Res Clin Oncol; 2023 Nov; 149(15):13855-13874. PubMed ID: 37535161
[TBL] [Abstract][Full Text] [Related]
10. [Single-cell transcriptome analysis of multigrade glioma heterogeneity and immune microenvironment revealed potential prognostic biomarkers].
Liu J; Xu K; Ma L; Wang Y
Sheng Wu Gong Cheng Xue Bao; 2022 Oct; 38(10):3790-3808. PubMed ID: 36305410
[TBL] [Abstract][Full Text] [Related]
11. Deciphering the role of QPCTL in glioma progression and cancer immunotherapy.
Liu Y; Lu S; Sun Y; Wang F; Yu S; Chen X; Wu LL; Yang H; Shi Y; Zhao K
Front Immunol; 2023; 14():1166377. PubMed ID: 37063864
[TBL] [Abstract][Full Text] [Related]
12. The molecular feature of macrophages in tumor immune microenvironment of glioma patients.
Zhang H; Luo YB; Wu W; Zhang L; Wang Z; Dai Z; Feng S; Cao H; Cheng Q; Liu Z
Comput Struct Biotechnol J; 2021; 19():4603-4618. PubMed ID: 34471502
[TBL] [Abstract][Full Text] [Related]
13. MD2 Is a Potential Biomarker Associated with Immune Cell Infiltration in Gliomas.
Zhao M; Li X; Chen Y; Wang S
Front Oncol; 2022; 12():854598. PubMed ID: 35372062
[TBL] [Abstract][Full Text] [Related]
14. Identification of the novel prognostic biomarker, MLLT11, reveals its relationship with immune checkpoint markers in glioma.
Chen L; Xiong Z; Zhao H; Teng C; Liu H; Huang Q; Wanggou S; Li X
Front Oncol; 2022; 12():889351. PubMed ID: 36033495
[TBL] [Abstract][Full Text] [Related]
15. Connective tissue growth factor as an unfavorable prognostic marker promotes the proliferation, migration, and invasion of gliomas.
Song ZB; Yang HP; Xu AQ; Zhan ZM; Song Y; Li ZY
Chin Med J (Engl); 2020 Mar; 133(6):670-678. PubMed ID: 32197031
[TBL] [Abstract][Full Text] [Related]
16. CHI3L2 Is a Novel Prognostic Biomarker and Correlated With Immune Infiltrates in Gliomas.
Liu L; Yang Y; Duan H; He J; Sun L; Hu W; Zeng J
Front Oncol; 2021; 11():611038. PubMed ID: 33937022
[TBL] [Abstract][Full Text] [Related]
17. CENPA acts as a prognostic factor that relates to immune infiltrates in gliomas.
Wang B; Wei W; Long S; Wang L; Yang B; Wu D; Li Z; Li Z; Arshad M; Li X; Chen J
Front Neurol; 2022; 13():1015221. PubMed ID: 36341103
[TBL] [Abstract][Full Text] [Related]
18. LRRFIP1, an epigenetically regulated gene, is a prognostic biomarker and predicts malignant phenotypes of glioma.
Ma W; Bao Z; Qian Z; Zhang K; Fan W; Xu J; Ren C; Zhang Y; Jiang T
CNS Neurosci Ther; 2022 Jun; 28(6):873-883. PubMed ID: 35338570
[TBL] [Abstract][Full Text] [Related]
19. The expression of Hexokinase 2 and its hub genes are correlated with the prognosis in glioma.
Huang Y; Ouyang F; Yang F; Zhang N; Zhao W; Xu H; Yang X
BMC Cancer; 2022 Aug; 22(1):900. PubMed ID: 35982398
[TBL] [Abstract][Full Text] [Related]
20. Glutamate metabotropic receptor 4 (GRM4) inhibits cell proliferation, migration and invasion in breast cancer and is regulated by miR-328-3p and miR-370-3p.
Xiao B; Chen D; Zhou Q; Hang J; Zhang W; Kuang Z; Sun Z; Li L
BMC Cancer; 2019 Sep; 19(1):891. PubMed ID: 31492116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
